Bioengineering strategies for inducing tolerance in autoimmune diabetes

Publication date: Available online 15 June 2017
Source:Advanced Drug Delivery Reviews
Author(s): Steinunn Baekkeskov, Jeffrey A. Hubbell, Edward A. Phelps
Type 1 diabetes is an autoimmune disease marked by the destruction of insulin-producing beta cells in the pancreatic islets. Strategies to delay onset or prevent the autoimmune recognition of beta cell antigens or T cell-mediated killing of beta cells have mainly focused on systemic immunomodulation and antigen-specific immunotherapy. To bridge the fields of type 1 diabetes immunology and biomaterials engineering, this article will review recent trends in the etiology of type 1 diabetes immunopathology and will focus on the contributions of emerging bioengineered strategies in the fight against beta cell autoimmunity in type 1 diabetes.

Graphical abstract

http://ift.tt/2sGgvaJ